Extracellular microRNAs in bronchoalveolar lavage samples from patients with lung diseases as predictors for lung cancer

Clinica Chimica Acta

Volumn 450, Issue , 2015, Pages 78-82

  Rehbein, Grit ^a   Schmidt, Bernd ^a   Fleischhacker, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Bronchial lavage samples; Extracellular microRNA; Lung cancer; QRT PCR

Indexed keywords

HSA MIR 1285; HSA MIR 1289; HSA MIR 1303; HSA MIR 19B 1; HSA MIR 217; HSA MIR 29A 5P; HSA MIR 548 3P; HSA MIR 650; MICRORNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; DNA MICROARRAY; EXTRACELLULAR SPACE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION;

BIOMARKERS, TUMOR; BRONCHOALVEOLAR LAVAGE; EXTRACELLULAR SPACE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84938877629     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.07.027     Document Type: Article

References (48)

1. Schottenfeld D., Beebe-Dimmer J.L., Buffler P.A., Omenn G.S. Current perspective on the global and United States cancer burden attributable to lifestyle and environmental risk factors. Annu. Rev. Public Health 2013, 34:97-117.
2. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2013. Ann. Oncol. 2013, 24:792-800.
3. Del Vescovo V., Grasso M., Barbareschi M., Denti M.A. MicroRNAs as lung cancer biomarkers. World J. Clin. Oncol. 2014, 5:604-620.
4. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
5. Kong Y.W., Ferland-McCollough D., Jackson T.J., Bushell M. MicroRNAs in cancer management. Lancet Oncol. 2012, 13:e249-e258.
6. Lin P.Y., Yu S.L., Yang P.C. MicroRNA in lung cancer. Br. J. Cancer 2010, 103:1144-1148.
7. Iorio M.V., Ferracin M., Liu C.G., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
8. Roldo C., Missiaglia E., Hagan J.P., et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24:4677-4684.
9. Wang Q., Wang S., Wang H., Li P., Ma Z. MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment. Exp. Biol. Med. (Maywood) 2012, 237:227-235.
10. Weber J.A., Baxter D.H., Zhang S., et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56:1733-1741.
11. Mitchell P.S., Parkin R.K., Kroh E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
12. Zen K., Zhang C.Y. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med. Res. Rev. 2012, 32:326-348.
13. Hunter M.P., Ismail N., Zhang X., et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3:e3694.
14. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285:17442-17452.
15. Arroyo J.D., Chevillet J.R., Kroh E.M., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5003-5008.
16. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
17. Levanen B., Bhakta N.R., Torregrosa Paredes P., et al. Altered microRNA profiles in bronchoalveolar lavage fluid exosomes in asthmatic patients. J. Allergy Clin. Immunol. 2013, 131:894-903.
18. Rodriguez M., Silva J., Lopez-Alfonso A., et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer 2014, 53:713-724.
19. Molina-Pinelo S., Suarez R., Pastor M.D., et al. Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis. Markers 2012, 32:221-230.
20. Bianchi F., Nicassio F., Veronesi G., di Fiore P.P. Circulating microRNAs: next-generation biomarkers for early lung cancer detection. Ecancermedicalscience 2012, 6:246.
21. Heegaard N.H., Schetter A.J., Welsh J.A., Yoneda M., Bowman E.D., Harris C.C. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int. J. Cancer 2012, 130:1378-1386.
22. Hennessey P.T., Sanford T., Choudhary A., et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 2012, 7:e32307.
23. Shin Y.M., Yun J., Lee O.J., et al. Diagnostic value of circulating extracellular miR-134, miR-185, and miR-22 levels in lung adenocarcinoma-associated malignant pleural effusion. Cancer Res. Treat. 2014, 46:178-185.
24. Wang Z.X., Bian H.B., Wang J.R., Cheng Z.X., Wang K.M., De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J. Surg. Oncol. 2011, 104:847-851.
25. Benz F., Roderburg C., Vargas Cardenas D., et al. U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. Exp. Mol. Med. 2013, 45:e42.
26. Lamba V., Ghodke-Puranik Y., Guan W., Lamba J.K. Identification of suitable reference genes for hepatic microRNA quantitation. BMC Res. Notes 2014, 7:129.
27. Peltier H.J., Latham G.J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14:844-852.
28. Sanders I., Holdenrieder S., Walgenbach-Brunagel G., et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int. J. Urol. 2012, 19:1017-1025.
29. Tang G., Shen X., Lv K., Wu Y., Bi J., Shen Q. Different normalization strategies might cause inconsistent variation in circulating microRNAs in patients with hepatocellular carcinoma. Med. Sci. Monit. 2015, 21:617-624.
30. Tian S., Huang S., Wu S., Guo W., Li J., He X. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3' untranslated region. Biochem. Biophys. Res. Commun. 2010, 396:435-439.
31. Zhang S.J., Feng J.F., Wang L., et al. miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells. Dig. Dis. Sci. 2014, 59(8):1754-1763.
32. El-Murr N., Abidi Z., Wanherdrick K., et al. MiRNA genes constitute new targets for microsatellite instability in colorectal cancer. PLoS One 2012, 7:e31862.
33. Sun B., Pu B., Chu D., Chu X., Li W., Wei D. MicroRNA-650 expression in glioma is associated with prognosis of patients. J. Neuro-Oncol. 2013, 115:375-380.
34. Huang J.Y., Cui S.Y., Chen Y.T., et al. MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One 2013, 8:e72615.
35. Wu H., Haag D., Muley T., et al. Tumor-microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma. Genes Chromosomes Cancer 2013, 52:250-264.
36. Zhang X., Zhu W., Zhang J., et al. MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem. Biophys. Res. Commun. 2010, 395:275-280.
37. Wang Y., Zhang X., Li H., Yu J., Ren X. The role of miRNA-29 family in cancer. Eur. J. Cell Biol. 2013, 92:123-128.
38. Zhou C., Chen H., Han L., Wang A., Chen L.A. Identification of featured biomarkers in different types of lung cancer with DNA microarray. Mol. Biol. Rep. 2014, 41(10):6357-6363.
39. Schmitt M.J., Margue C., Behrmann I., Kreis S. MiRNA-29: a microRNA family with tumor-suppressing and immune-modulating properties. Curr. Mol. Med. 2013, 13:572-585.
40. Fabbri M., Paone A., Calore F., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2110-E2116.
41. Berger F., Reiser M.F. Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences?. Theranostics 2013, 3:943-952.
42. Jarry J., Schadendorf D., Greenwood C., Spatz A., van Kempen L.C. The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol. Oncol. 2014, 8:819-829.
43. Zhu J., Zheng Z., Wang J., et al. Different miRNA expression profiles between human breast cancer tumors and serum. Front. Genet. 2014, 5:149.
44. Aushev V.N., Zborovskaya I.B., Laktionov K.K., et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One 2013, 8:e78649.
45. Meisgen F., Xu N., Wei T., et al. MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp. Dermatol. 2012, 21:312-314.
46. Wang T., Feng Y., Sun H., et al. miR-21 regulates skin wound healing by targeting multiple aspects of the healing process. Am. J. Pathol. 2012, 181:1911-1920.
47. Angulo M., Lecuona E., Sznajder J.I. Role of MicroRNAs in lung disease. Arch. Bronconeumol. 2012, 48:325-330.
48. Wang J., Huang S.K., Zhao M., et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One 2014, 9:e87451.